Table 3 Candidate vaccines for COVID-19 (as of June, 2021)
From: Current status of traditional Chinese medicine for the treatment of COVID-19 in China
Vaccine platform description | Candidate vaccines in clinical phase (No.) | Candidate vaccines in pre-clinical phase (No.) |
|---|---|---|
Protein subunit | 32 | 72 |
Viral vector (non-replicating) | 16 | 21 |
Inactivated virus | 16 | 9 |
RNA based vaccine | 16 | 24 |
DNA based vaccine | 10 | 16 |
Virus like particle | 5 | 18 |
Viral vector (replicating) | 2 | 19 |
Viral vector (replicating) + antigen presenting cell | 2 | 0 |
Live attenuated virus | 2 | 2 |
Live attenuated bacterial vector | 0 | 2 |
Viral vector (non-replicating) + antigen presenting cell | 1 | 0 |
Bacterial vector (Replicating) | 0 | 1 |
Cellular based vaccine | 0 | 1 |
Total | 102 | 185 |